228 related articles for article (PubMed ID: 35833321)
1. NK cell dysfunction is linked with disease severity in SARS-CoV-2 patients.
Dizaji Asl K; Mazloumi Z; Majidi G; Kalarestaghi H; Sabetkam S; Rafat A
Cell Biochem Funct; 2022 Aug; 40(6):559-568. PubMed ID: 35833321
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cell exhaustion in SARS-CoV-2 infection.
Gallardo-Zapata J; Maldonado-Bernal C
Innate Immun; 2022 Aug; 28(6):189-198. PubMed ID: 35733383
[TBL] [Abstract][Full Text] [Related]
3. Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications.
Di Vito C; Calcaterra F; Coianiz N; Terzoli S; Voza A; Mikulak J; Della Bella S; Mavilio D
Front Immunol; 2022; 13():888248. PubMed ID: 35844604
[TBL] [Abstract][Full Text] [Related]
4. Is IFN expression by NK cells a hallmark of severe COVID-19?
Csordas BG; de Sousa Palmeira PH; Peixoto RF; Comberlang FCQDDS; de Medeiros IA; Azevedo FLAA; Veras RC; Janebro DI; Amaral IPG; Barbosa-Filho JM; Keesen TSL
Cytokine; 2022 Sep; 157():155971. PubMed ID: 35908408
[TBL] [Abstract][Full Text] [Related]
5. NK cells in COVID-19-from disease to vaccination.
Hammer Q; Cuapio A; Bister J; Björkström NK; Ljunggren HG
J Leukoc Biol; 2023 Oct; 114(5):507-512. PubMed ID: 36976012
[TBL] [Abstract][Full Text] [Related]
6. Elevated Exhaustion Levels of NK and CD8
Li M; Guo W; Dong Y; Wang X; Dai D; Liu X; Wu Y; Li M; Zhang W; Zhou H; Zhang Z; Lin L; Kang Z; Yu T; Tian C; Qin R; Gui Y; Jiang F; Fan H; Heissmeyer V; Sarapultsev A; Wang L; Luo S; Hu D
Front Immunol; 2020; 11():580237. PubMed ID: 33154753
[TBL] [Abstract][Full Text] [Related]
7. Defining the role of natural killer cells in COVID-19.
Lee MJ; Blish CA
Nat Immunol; 2023 Oct; 24(10):1628-1638. PubMed ID: 37460639
[TBL] [Abstract][Full Text] [Related]
8. NK cells from COVID-19 positive patients exhibit enhanced cytotoxic activity upon NKG2A and KIR2DL1 blockade.
Lee G; Schauner R; Burke J; Borocz J; Vasana S; Sobieraj L; Giraudo M; Jackson Z; Ansari Q; Navas M; Sakr H; Wald D
Front Immunol; 2023; 14():1022890. PubMed ID: 37483595
[TBL] [Abstract][Full Text] [Related]
9. Expansion of CD56
Casado JL; Moraga E; Vizcarra P; Velasco H; Martín-Hondarza A; Haemmerle J; Gómez S; Quereda C; Vallejo A
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062250
[TBL] [Abstract][Full Text] [Related]
10. Plasticity of natural killer cells in pregnant patients infected with SARS-CoV-2 and their neonates during childbirth.
Carbonnel M; Daclin C; Tarantino N; Groiseau O; Morin V; Rousseau A; Vasse M; Hertig A; Kennel T; Ayoubi JM; Vieillard V
Front Immunol; 2022; 13():893450. PubMed ID: 35911747
[TBL] [Abstract][Full Text] [Related]
11. Exploring the Utility of NK Cells in COVID-19.
Deng X; Terunuma H; Nieda M
Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625739
[TBL] [Abstract][Full Text] [Related]
12. Immune characterization of a Colombian family cluster with SARS-CoV-2 infection.
Aguilar-Jiménez W; Flórez-Álvarez L; Rincón DS; Marín-Palma D; Sánchez-Martínez A; Martínez J; Zapata MI; Loaiza JD; Cárdenas C; Guzmán F; Velilla PA; Taborda NA; Zapata W; Hernández JC; Díaz FJ; Rugeles MT
Biomedica; 2021 Oct; 41(Sp. 2):86-102. PubMed ID: 34669281
[TBL] [Abstract][Full Text] [Related]
13. CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines
Ma MT; Badeti S; Chen CH; Kim J; Choudhary A; Honnen B; Reichman C; Calianese D; Pinter A; Jiang Q; Shi L; Zhou R; Xu H; Li Q; Gause W; Liu D
Front Immunol; 2021; 12():652223. PubMed ID: 34367128
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 pneumonia: CD8
Jiang Y; Wei X; Guan J; Qin S; Wang Z; Lu H; Qian J; Wu L; Chen Y; Chen Y; Lin X
Clin Immunol; 2020 Sep; 218():108516. PubMed ID: 32574709
[TBL] [Abstract][Full Text] [Related]
15. The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.
Jewett A
Front Immunol; 2020; 11():1692. PubMed ID: 32754162
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients.
Hagemann K; Riecken K; Jung JM; Hildebrandt H; Menzel S; Bunders MJ; Fehse B; Koch-Nolte F; Heinrich F; Peine S; Schulze Zur Wiesch J; Brehm TT; Addo MM; Lütgehetmann M; Altfeld M
Eur J Immunol; 2022 Aug; 52(8):1297-1307. PubMed ID: 35416291
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells.
Hammer Q; Dunst J; Christ W; Picarazzi F; Wendorff M; Momayyezi P; Huhn O; Netskar HK; Maleki KT; García M; Sekine T; Sohlberg E; Azzimato V; Aouadi M; ; ; Degenhardt F; Franke A; Spallotta F; Mori M; Michaëlsson J; Björkström NK; Rückert T; Romagnani C; Horowitz A; Klingström J; Ljunggren HG; Malmberg KJ
Cell Rep; 2022 Mar; 38(10):110503. PubMed ID: 35235832
[TBL] [Abstract][Full Text] [Related]
18. Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection.
Christodoulou I; Rahnama R; Ravich JW; Seo J; Zolov SN; Marple AN; Markovitz DM; Bonifant CL
Front Immunol; 2021; 12():763460. PubMed ID: 35003077
[TBL] [Abstract][Full Text] [Related]
19. Age-dependent NK cell dysfunctions in severe COVID-19 patients.
Fionda C; Ruggeri S; Sciumè G; Laffranchi M; Quinti I; Milito C; Palange P; Menichini I; Sozzani S; Frati L; Gismondi A; Santoni A; Stabile H
Front Immunol; 2022; 13():1039120. PubMed ID: 36466890
[TBL] [Abstract][Full Text] [Related]
20. Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection.
Littera R; Chessa L; Deidda S; Angioni G; Campagna M; Lai S; Melis M; Cipri S; Firinu D; Santus S; Lai A; Porcella R; Rassu S; Meloni F; Schirru D; Cordeddu W; Kowalik MA; Ragatzu P; Vacca M; Cannas F; Alba F; Carta MG; Del Giacco S; Restivo A; Deidda S; Palimodde A; Congera P; Perra R; Orrù G; Pes F; Loi M; Murru C; Urru E; Onali S; Coghe F; Giglio S; Perra A
PLoS One; 2021; 16(8):e0255608. PubMed ID: 34352002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
